<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325529</url>
  </required_header>
  <id_info>
    <org_study_id>2020A000886</org_study_id>
    <nct_id>NCT04325529</nct_id>
  </id_info>
  <brief_title>Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.2 (Stress Manipulation)</brief_title>
  <official_title>Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates how remitted individuals with past major depressive disorder (MDD)&#xD;
      make approach-avoidance decisions and which brain regions are implicated in such decisions.&#xD;
      Information collected through MRI and behavioral tasks will be used to predict depressive&#xD;
      symptoms in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overarching goals of this research are to investigate: (1) neural substrates of&#xD;
      approach/avoidance behaviors in remitted MDDs; (2) stress-induced signaling in remitted&#xD;
      individuals with past MDD; (3) neural markers that prospectively predict disease course.&#xD;
&#xD;
      This will be achieved through an innovative method of using functional magnetic resonance&#xD;
      imaging (fMRI) during an approach/avoidance decision-making task.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Interview</measure>
    <time_frame>Baseline</time_frame>
    <description>For assessing psychological state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral Performance on the Probabilistic Reward Task (PRT)</measure>
    <time_frame>Baseline</time_frame>
    <description>The Probablilistic Reward Task assesses positive reinforcement learning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI Data</measure>
    <time_frame>MRI scans take place within 30 days of Screening Visit</time_frame>
    <description>For testing the neural correlates of approach-avoidance decision making behaviors in a trans-diagnostic sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Salivary Cortisol</measure>
    <time_frame>Baseline</time_frame>
    <description>For assessing stress level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up Clinical interviews</measure>
    <time_frame>Change from Baseline at 6 months and 12 months after the MRI scanning visit</time_frame>
    <description>To assess psychological state changes</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Major Depression in Remission</condition>
  <arm_group>
    <arm_group_label>remitted MDD</arm_group_label>
    <description>Unmedicated Remitted Participants with Past History of MDD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <description>healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aversive stimuli</intervention_name>
    <description>Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).</description>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_label>remitted MDD</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      saliva sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects for this research will be 96 participants recruited from the community by the&#xD;
        Center for Depression, Anxiety and Stress Research (Director: Dr. Diego Pizzagalli, Ph.D.).&#xD;
        Participants will include: (1) 48 participants with past MDD; and (2) 48 demographically&#xD;
        matched healthy controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for all participants:&#xD;
&#xD;
          -  All genders, races, and ethnic origins, aged between 18 and 45&#xD;
&#xD;
          -  Capable of providing written informed consent, and fluent in English&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  Absence of any psychotropic medications for at least 2 weeks&#xD;
&#xD;
          -  Has a smartphone (iPhone or Android) (needed for Ecological Momentary Assessment)&#xD;
&#xD;
        Inclusion Criteria for &quot;Remitted MDD&quot; group:&#xD;
&#xD;
          -  Meets inclusion criteria for all subjects, plus:&#xD;
&#xD;
          -  History of MDD as defined by DSM-5&#xD;
&#xD;
          -  Absence of anxiety disorder for the past two months&#xD;
&#xD;
        Exclusion Criteria for all participants:&#xD;
&#xD;
          -  Subjects with suicidal ideation where outpatient treatment is determined unsafe by the&#xD;
             study clinician. These patients will be immediately referred to appropriate clinical&#xD;
             treatment&#xD;
&#xD;
          -  Pregnant women or women of childbearing potential who are not using a medically&#xD;
             accepted means of contraception (defined as oral contraceptive pill or implant,&#xD;
             condom, diaphragm, spermicide, IUD, s/p tubal ligation, or partner with vasectomy)&#xD;
&#xD;
          -  Serious or unstable medical illness, including cardiovascular, hepatic, renal,&#xD;
             respiratory, endocrine, neurologic or hematologic disease&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  History of psychiatric illnesses, other than depression or anxiety disorders among the&#xD;
             Current MDD and Remitted MDD groups&#xD;
&#xD;
          -  History of substance use disorder or alcohol use disorder (as these terms are defined&#xD;
             by DSM-5); except depressed subjects may have a history of 'Mild' substance/alcohol&#xD;
             use disorder only if it ended as least 12 months ago&#xD;
&#xD;
          -  History of cocaine or stimulant use or dopaminergic drugs&#xD;
&#xD;
          -  History or current diagnosis of dementia, or a score of &lt; 26 on the Mini Mental State&#xD;
             Examination at the screening visit;&#xD;
&#xD;
          -  Patients with mood congruent or mood incongruent psychotic features&#xD;
&#xD;
          -  Current use of other psychotropic drugs&#xD;
&#xD;
          -  Clinical or laboratory evidence of hypothyroidism&#xD;
&#xD;
          -  Patients with a lifetime history of electroconvulsive therapy (ECT)&#xD;
&#xD;
          -  Failure to meet standard MRI safety requirements&#xD;
&#xD;
          -  Abnormal ECG and lab results&#xD;
&#xD;
          -  History of seizure disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diego Pizzagalli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Blank, BA</last_name>
    <phone>617-855-4425</phone>
    <email>jmblank@mclean.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Crowley, ALM</last_name>
    <phone>617-855-4432</phone>
    <email>djcrowley@mclean.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Crowley</last_name>
      <phone>617-855-4432</phone>
      <email>djcrowley@mclean.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Diego Pizzagalli, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Diego A. Pizzagalli</investigator_full_name>
    <investigator_title>Principal Investigator; Professor, Department of Psychiatry, Harvard Medical School, Mclean Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

